{"id":57111,"date":"2026-02-13T19:30:50","date_gmt":"2026-02-13T11:30:50","guid":{"rendered":"https:\/\/flcube.com\/?p=57111"},"modified":"2026-02-13T19:30:51","modified_gmt":"2026-02-13T11:30:51","slug":"bio-theras-gotenfia-wins-european-approval-as-simponi-biosimilar","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=57111","title":{"rendered":"Bio-Thera\u2019s Gotenfia Wins European Approval as Simponi Biosimilar"},"content":{"rendered":"\n

Bio-Thera Solutions Inc.<\/strong> (SHA:\u202f688177<\/a><\/strong>) announced that the European Commission (EC)<\/strong> has approved Gotenfia (BAT2506)<\/strong>, its biosimilar of Johnson & Johnson’s Simponi (golimumab)<\/strong>, for five autoimmune indications<\/strong>: rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, ulcerative colitis, and juvenile idiopathic arthritis<\/strong>. The TNF-\u03b1 monoclonal antibody biosimilar<\/strong>, licensed to STADA Arzneimittel AG<\/strong> for EU\/UK\/Switzerland commercialization<\/strong>, marks Bio-Thera’s first major European regulatory success<\/strong> and expands its global biosimilar footprint<\/strong>.<\/p>\n\n\n\n

Regulatory Milestone<\/h2>\n\n\n\n
Element<\/th>Detail<\/th><\/tr><\/thead>
Developer<\/strong><\/td>Bio-Thera Solutions Inc. (SHA:\u202f688177, China)<\/td><\/tr>
Reference Product<\/strong><\/td>Simponi (golimumab) \u2013 Johnson & Johnson<\/td><\/tr>
Biosimilar<\/strong><\/td>Gotenfia (BAT2506)<\/td><\/tr>
Regulatory Body<\/strong><\/td>European Commission (EC)<\/td><\/tr>
Approved Indications<\/strong><\/td>Rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, ulcerative colitis, juvenile idiopathic arthritis<\/td><\/tr>
Presentations<\/strong><\/td>50 mg\/0.5 mL and 100 mg\/mL prefilled syringes<\/td><\/tr>
Territory<\/strong><\/td>27 EU member states + Norway, Iceland, Liechtenstein<\/td><\/tr>
EU Commercial Partner<\/strong><\/td>STADA Arzneimittel AG (exclusive rights since May\u202f2024)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Product Profile & Development History<\/h2>\n\n\n\n
Feature<\/th>Gotenfia Specification<\/th>Strategic Context<\/th><\/tr><\/thead>
Mechanism<\/strong><\/td>TNF-\u03b1 monoclonal antibody inhibition<\/td>Established anti-inflammatory pathway; proven efficacy in autoimmune diseases<\/td><\/tr>
Biosimilar Development<\/strong><\/td>Per China, US, and EU guidelines<\/strong><\/td>Global regulatory alignment<\/strong>; interchangeability potential<\/strong><\/td><\/tr>
China Origin<\/strong><\/td>BAT2506<\/strong> approved 2018<\/strong> for ankylosing spondylitis and RA<\/td>Domestic manufacturing base<\/strong>; cost-competitive production<\/strong><\/td><\/tr>
STADA Partnership<\/strong><\/td>May\u202f2024 licensing deal<\/strong> \u2013 exclusive EU\/UK\/Switzerland rights<\/td>Commercial infrastructure leverage<\/strong>; market access acceleration<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Context & Competitive Positioning<\/h2>\n\n\n\n
Factor<\/th>Strategic Analysis<\/th><\/tr><\/thead>
Golimumab Market Size<\/strong><\/td>Simponi global sales ~$2 billion<\/strong>; EU represents ~30%<\/strong> (~$600M) of addressable market; biosimilar entry drives 30-50% price erosion<\/strong><\/td><\/tr>
TNF Biosimilar Competition<\/strong><\/td>Adalimumab (Humira)<\/strong>, etanercept (Enbrel)<\/strong>, infliximab (Remicade)<\/strong> biosimilars commoditized<\/strong>; golimumab biosimilar limited competition<\/strong> \u2013 first-mover advantage<\/strong> for Gotenfia in EU<\/td><\/tr>
STADA Commercial Strength<\/strong><\/td>Leading European generics\/biosimilars player<\/strong>; established hospital and pharmacy channels<\/strong>; payer relationships<\/strong> for rapid formulary adoption<\/strong><\/td><\/tr>
Bio-Thera Global Expansion<\/strong><\/td>EU approval validates CMC and clinical package<\/strong>; supports US FDA submission<\/strong>; template for additional biosimilar launches<\/strong><\/td><\/tr>
Autoimmune Disease Burden<\/strong><\/td>>10 million patients<\/strong> in EU with RA, PsA, AS, UC<\/strong>; biosimilar access expands treatment penetration<\/strong> and reduces healthcare costs<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Commercial Outlook<\/h2>\n\n\n\n
Phase<\/th>Activity<\/th>Timeline<\/th><\/tr><\/thead>
Current<\/strong><\/td>EC approval; STADA launch preparation<\/td>Q1\u202f2026<\/td><\/tr>
EU Launch<\/strong><\/td>Hospital and specialty pharmacy distribution; rheumatology\/gastroenterology education<\/td>Q2-Q3\u202f2026<\/td><\/tr>
Market Access<\/strong><\/td>National reimbursement negotiations; tender participation<\/td>2026-2027<\/td><\/tr>
US Expansion<\/strong><\/td>FDA biosimilar submission based on EU approval data<\/td>2026-2027<\/td><\/tr>
Pipeline<\/strong><\/td>Additional Bio-Thera biosimilars (bevacizumab, trastuzumab, adalimumab) leveraging EU regulatory pathway<\/td>2026+<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Forward\u2011Looking Statements<\/strong>
This brief contains forward\u2011looking statements regarding Gotenfia commercial launch success in Europe, STADA market execution, and Bio-Thera’s US biosimilar regulatory pathway. Actual results may differ due to competitive responses from other golimumab biosimilar developers, pricing pressure from national tender processes, and interchangeability designation timelines.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Bio-Thera Solutions Inc. (SHA:\u202f688177) announced that the European Commission (EC) has approved Gotenfia (BAT2506), its…<\/p>\n","protected":false},"author":1,"featured_media":57112,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[65,289,43,149,15,1055],"class_list":["post-57111","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-auto-immune","tag-bio-thera-solutions","tag-biosimilars","tag-johnson-johnson","tag-product-approvals","tag-sha-688177"],"yoast_head":"\nBio-Thera\u2019s Gotenfia Wins European Approval as Simponi Biosimilar - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Bio-Thera Solutions Inc. (SHA:\u202f688177) announced that the European Commission (EC) has approved Gotenfia (BAT2506), its biosimilar of Johnson & Johnson's Simponi (golimumab), for five autoimmune indications: rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, ulcerative colitis, and juvenile idiopathic arthritis. The TNF-\u03b1 monoclonal antibody biosimilar, licensed to STADA Arzneimittel AG for EU\/UK\/Switzerland commercialization, marks Bio-Thera's first major European regulatory success and expands its global biosimilar footprint.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=57111\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bio-Thera\u2019s Gotenfia Wins European Approval as Simponi Biosimilar\" \/>\n<meta property=\"og:description\" content=\"Bio-Thera Solutions Inc. (SHA:\u202f688177) announced that the European Commission (EC) has approved Gotenfia (BAT2506), its biosimilar of Johnson & Johnson's Simponi (golimumab), for five autoimmune indications: rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, ulcerative colitis, and juvenile idiopathic arthritis. The TNF-\u03b1 monoclonal antibody biosimilar, licensed to STADA Arzneimittel AG for EU\/UK\/Switzerland commercialization, marks Bio-Thera's first major European regulatory success and expands its global biosimilar footprint.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=57111\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-13T11:30:50+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-13T11:30:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1308.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57111#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57111\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Bio-Thera\u2019s Gotenfia Wins European Approval as Simponi Biosimilar\",\"datePublished\":\"2026-02-13T11:30:50+00:00\",\"dateModified\":\"2026-02-13T11:30:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57111\"},\"wordCount\":421,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57111#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/1308.webp\",\"keywords\":[\"Auto-immune\",\"Bio-Thera Solutions\",\"Biosimilars\",\"Johnson & Johnson\",\"Product approvals\",\"SHA: 688177\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=57111#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57111\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=57111\",\"name\":\"Bio-Thera\u2019s Gotenfia Wins European Approval as Simponi Biosimilar - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57111#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57111#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/1308.webp\",\"datePublished\":\"2026-02-13T11:30:50+00:00\",\"dateModified\":\"2026-02-13T11:30:51+00:00\",\"description\":\"Bio-Thera Solutions Inc. (SHA:\u202f688177) announced that the European Commission (EC) has approved Gotenfia (BAT2506), its biosimilar of Johnson & Johnson's Simponi (golimumab), for five autoimmune indications: rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, ulcerative colitis, and juvenile idiopathic arthritis. The TNF-\u03b1 monoclonal antibody biosimilar, licensed to STADA Arzneimittel AG for EU\\\/UK\\\/Switzerland commercialization, marks Bio-Thera's first major European regulatory success and expands its global biosimilar footprint.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57111#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=57111\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57111#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/1308.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/1308.webp\",\"width\":1080,\"height\":608,\"caption\":\"Bio-Thera\u2019s Gotenfia Wins European Approval as Simponi Biosimilar\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57111#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bio-Thera\u2019s Gotenfia Wins European Approval as Simponi Biosimilar\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Bio-Thera\u2019s Gotenfia Wins European Approval as Simponi Biosimilar - Insight, China's Pharmaceutical Industry","description":"Bio-Thera Solutions Inc. (SHA:\u202f688177) announced that the European Commission (EC) has approved Gotenfia (BAT2506), its biosimilar of Johnson & Johnson's Simponi (golimumab), for five autoimmune indications: rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, ulcerative colitis, and juvenile idiopathic arthritis. The TNF-\u03b1 monoclonal antibody biosimilar, licensed to STADA Arzneimittel AG for EU\/UK\/Switzerland commercialization, marks Bio-Thera's first major European regulatory success and expands its global biosimilar footprint.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=57111","og_locale":"en_US","og_type":"article","og_title":"Bio-Thera\u2019s Gotenfia Wins European Approval as Simponi Biosimilar","og_description":"Bio-Thera Solutions Inc. (SHA:\u202f688177) announced that the European Commission (EC) has approved Gotenfia (BAT2506), its biosimilar of Johnson & Johnson's Simponi (golimumab), for five autoimmune indications: rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, ulcerative colitis, and juvenile idiopathic arthritis. The TNF-\u03b1 monoclonal antibody biosimilar, licensed to STADA Arzneimittel AG for EU\/UK\/Switzerland commercialization, marks Bio-Thera's first major European regulatory success and expands its global biosimilar footprint.","og_url":"https:\/\/flcube.com\/?p=57111","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-13T11:30:50+00:00","article_modified_time":"2026-02-13T11:30:51+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1308.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=57111#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=57111"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Bio-Thera\u2019s Gotenfia Wins European Approval as Simponi Biosimilar","datePublished":"2026-02-13T11:30:50+00:00","dateModified":"2026-02-13T11:30:51+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=57111"},"wordCount":421,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=57111#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1308.webp","keywords":["Auto-immune","Bio-Thera Solutions","Biosimilars","Johnson & Johnson","Product approvals","SHA: 688177"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=57111#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=57111","url":"https:\/\/flcube.com\/?p=57111","name":"Bio-Thera\u2019s Gotenfia Wins European Approval as Simponi Biosimilar - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=57111#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=57111#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1308.webp","datePublished":"2026-02-13T11:30:50+00:00","dateModified":"2026-02-13T11:30:51+00:00","description":"Bio-Thera Solutions Inc. (SHA:\u202f688177) announced that the European Commission (EC) has approved Gotenfia (BAT2506), its biosimilar of Johnson & Johnson's Simponi (golimumab), for five autoimmune indications: rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, ulcerative colitis, and juvenile idiopathic arthritis. The TNF-\u03b1 monoclonal antibody biosimilar, licensed to STADA Arzneimittel AG for EU\/UK\/Switzerland commercialization, marks Bio-Thera's first major European regulatory success and expands its global biosimilar footprint.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=57111#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=57111"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=57111#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1308.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1308.webp","width":1080,"height":608,"caption":"Bio-Thera\u2019s Gotenfia Wins European Approval as Simponi Biosimilar"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=57111#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Bio-Thera\u2019s Gotenfia Wins European Approval as Simponi Biosimilar"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1308.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/57111","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=57111"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/57111\/revisions"}],"predecessor-version":[{"id":57113,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/57111\/revisions\/57113"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/57112"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=57111"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=57111"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=57111"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}